Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan for exercise-induced pulmonary arterial hypertension in congenital heart disease
NL-OMON40031Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pulmonary arterial hypertension (PAH) and Cardiovascular Malformation (CVM) comparing Bosentan with Placebo (2 arms). Primary endpoint: Change in mean pulmonary arterial pressure at peak exercise. Started Jun 2013; status: active, not recruiting.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on NL-OMON40031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40031.